A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008781/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of
maribavir administered orally for up to 24 weeks for treatment of CMV infections that are
resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in
recipients of stem cell or solid organ transplants.
提供机构：
Vivli
创建时间：
2023-02-10
